Vutrisiran Market Analysis 2026: Market Size, Growth Trends And Industry Outlook
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
#Vutrisiran Market Forecast: Value Set To Climb From $0.75 Billion To $1.18 Billion#_x000D_
The vutrisiran market has experienced rapid expansion in recent years. It is projected to expand from $0.67 billion in 2025 to $0.75 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.1%. Historically, this growth has been driven by factors such as significant siRNA approval breakthroughs, persistent unmet requirements in hATTR amyloidosis, restrictions associated with liver transplant procedures, the broadening of orphan drug regulations, and advancements in genetic diagnostic methods._x000D_
_x000D_
The vutrisiran market size is projected to experience substantial expansion in the coming years, reaching $1.18 billion in 2030, driven by a compound annual growth rate (CAGR) of 12.0%. This growth throughout the forecast period is primarily fueled by increasing awareness of rare diseases, the broadening pipeline of RNA therapeutics, the growing acceptance of long-acting treatments, enhanced genetic screening initiatives, and the proliferation of specialty care facilities. Prominent trends anticipated during this period include the expanding adoption of RNA interference therapies, a heightened focus on rare genetic conditions, the development of treatments with extended dosing intervals, a rising demand for targeted amyloidosis therapies, and the increased application of subcutaneous RNA drugs._x000D_
_x000D_
#Get A Free Sample Report With In-Depth Market Insights:#_x000D_
_x000D_
#Vutrisiran Market Growth Drivers: What’s Behind The Acceleration?#_x000D_
Future expansion of the vutrisiran market is anticipated to be fueled by growing investments in research and development. Research and development (R&D) encompasses the systematic exploration and experimentation aimed at innovating and enhancing products, services, or processes. This rise in R&D investment stems from government support and funding, the escalating demands of the healthcare and pharmaceutical sectors, and increasing focus on sustainability and environmental issues. Financial backing for R&D enables pharmaceutical firms to undertake clinical trials, thereby proving the enduring efficacy and safety of drugs, which facilitates wider regulatory clearances. Furthermore, progress in RNA interference (RNAi) technology enhances the drug’s accuracy, resulting in fewer side effects and greater patient acceptance. As an illustration, according to the Office for National Statistics, a UK government department, in April 2025, the UK government’s net expenditure on research and development (R&D) climbed to roughly US $22.9 billion (£17.4 billion) in 2023, marking an increase from approximately US $20.0 billion (£16.1 billion) in 2022. Consequently, the expanding financial commitment to research and development is propelling the expansion of the vutrisiran market._x000D_
_x000D_
#Vutrisiran Market Segment Outlook: Which Categories Are Growing Fastest?#_x000D_
The vutrisiran market covered in this report is segmented – _x000D_
_x000D_
1) By Drug Class: RNA Interference (RNAi) Therapeutics, GalNAc-Conjugated Nucleic Acid Drugs, Synthetic RNA-Based Therapeutics_x000D_
2) By Route Of Administration: Injectable, Subcutaneous_x000D_
3) By Patient Demographics: Adult, Geriatric_x000D_
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels_x000D_
_x000D_
Subsegments:_x000D_
1) By RNA Interference (RNAi) Therapeutics: Small Interfering RNA (siRNA) Drugs, Gene-Silencing RNA Therapies_x000D_
2) By GalNAc-Conjugated Nucleic Acid Drugs: GalNAc-Conjugated siRNA Therapies, Hepatocyte-Targeted RNA Therapeutics_x000D_
3) By Synthetic RNA-Based Therapeutics: Chemically Modified RNA Therapeutics, Long-Acting RNA Therapeutics_x000D_
_x000D_
#Vutrisiran Market Trends: What’s Defining The Industry’s Next Phase?#_x000D_
Major companies in the vutrisiran market are extending its application to cardiomyopathy through regulatory approval, such as supplemental indications for ATTR CM, with the goal of broadening the patient base and maximizing long-term value. A supplemental new drug application (sNDA) is a regulatory submission that allows an approved drug to be used for new indications. For instance, in March 2025, Alnylam Pharmaceuticals, a US-based biotech company, obtained FDA approval for AMVUTTRA (vutrisiran) in adult patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM), making it the first RNAi therapeutic approved for both polyneuropathy and cardiomyopathy types of the condition. Thus, the expansion into cardiomyopathy is a crucial trend driving growth in the vutrisiran market by increasing its clinical reach and patient access._x000D_
_x000D_
#Vutrisiran Market Leading Companies And Competitive Benchmarking#_x000D_
Major companies operating in the vutrisiran market are Alnylam Pharmaceuticals Inc _x000D_
_x000D_
#View The Full Vutrisiran Market Report:#_x000D_
_x000D_
#Vutrisiran Market Geographic Distribution And Regional Opportunities#_x000D_
North America was the largest region in the vutrisiran market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vutrisiran market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out To Our Team:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas: +1 310-496-7795_x000D_
Asia: +44 7882 955267 & +91 8897263534_x000D_
Europe: +44 7882 955267_x000D_
Email us at: marketing@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
